Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Crohn's Disease
Interventions
DRUG

Infliximab

Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms

DRUG

Infliximab

Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)

DRUG

Infliximab

Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time

Trial Locations (12)

31403

Chu Toulouse, Toulouse

33700

CHU Bordeaux - Pessac, Pessac

35033

Chu Rennes, Rennes

37044

Chu Tours, Tours

51000

Chu Reims, Reims

54500

Chu Nancy, Vandœuvre-lès-Nancy

63003

Chu Clermont-Ferrand, Clermont-Ferrand

75010

Hopital Saint Louis, Paris

80054

Chu Amiens, Amiens

92110

Hopital Beaujon, Clichy

Unknown

CHRU Lille, Lille

06202

CHU NICE, Nice

All Listed Sponsors
lead

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

OTHER

NCT01442025 - Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease | Biotech Hunter | Biotech Hunter